---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000013"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:56:09.467192+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023

## Summary
- Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.
- Net loss of $42.9M for FY2022 vs $100.6M in 2021 (which included $81.2M non-cash charge).
- Phase 1 INTERCEPT-AD trial of ACU193 in early Alzheimer's completed enrollment Feb 2023; topline data expected Q3 2023.
- Protocol amendment reduced cohort 7 dose to 25 mg/kg Q2W after blinded PK/SA, 2 asymptomatic ARIA-E cases noted.
- FDA granted Fast Track designation for ACU193 in Oct 2022; Derrell Porter, M.D. joined board in Jan 2023.

## SEC filing metadata
- accession: 0001576885-23-000013
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/0001576885-23-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/abos-20230327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000013
- JSON: https://secwatch.observer/filing/0001576885-23-000013.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000013.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 27, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/0001576885-23-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.